XML 45 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill And Other Intangibles (Tables)
3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
The carrying amounts of goodwill at March 31, 2019 and December 31, 2018 are net of the following accumulated impairments (in thousands):
 
Branded Pharmaceuticals
 
Sterile Injectables
 
Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2018
$
855,810

 
$

 
$
2,991,549

 
$
456,408

 
$
4,303,767

Accumulated impairment losses as of March 31, 2019
$
855,810

 
$

 
$
3,077,549

 
$
466,317

 
$
4,399,676

Changes in the carrying amount of our goodwill for the three months ended March 31, 2019 were as follows (in thousands):
 
Branded Pharmaceuticals
 
Sterile Injectables
 
Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2018
$
828,818

 
$
2,731,193

 
$
151,108

 
$
53,517

 
$
3,764,636

Effect of currency translation

 

 

 
1,165

 
1,165

Goodwill impairment charges

 

 
(86,000
)
 

 
(86,000
)
Goodwill as of March 31, 2019
$
828,818

 
$
2,731,193

 
$
65,108

 
$
54,682

 
$
3,679,801

Schedule of other intangible assets
Changes in the amount of other intangible assets for the three months ended March 31, 2019 are set forth in the table below (in thousands).
Cost basis:
Balance as of December 31, 2018
 
Acquisitions
 
Impairments
 
Effect of Currency Translation
 
Balance as of March 31, 2019
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
In-process research and development
$
93,900

 
$

 
$

 
$

 
$
93,900

Total indefinite-lived intangibles
$
93,900

 
$

 
$

 
$

 
$
93,900

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 14 years)
$
457,402

 
$

 
$

 
$

 
$
457,402

Tradenames
6,409

 

 

 

 
6,409

Developed technology (weighted average life of 11 years)
6,182,015

 

 
(78,700
)
 
5,356

 
6,108,671

Total finite-lived intangibles (weighted average life of 11 years)
$
6,645,826

 
$

 
$
(78,700
)
 
$
5,356

 
$
6,572,482

Total other intangibles
$
6,739,726

 
$

 
$
(78,700
)
 
$
5,356

 
$
6,666,382

 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2018
 
Amortization
 
Impairments
 
Effect of Currency Translation
 
Balance as of March 31, 2019
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
Licenses
$
(398,182
)
 
$
(4,869
)
 
$

 
$

 
$
(403,051
)
Tradenames
(6,409
)
 

 

 

 
(6,409
)
Developed technology
(2,877,829
)
 
(140,730
)
 

 
(2,769
)
 
(3,021,328
)
Total other intangibles
$
(3,282,420
)
 
$
(145,599
)
 
$

 
$
(2,769
)
 
$
(3,430,788
)
Net other intangibles
$
3,457,306

 
 
 
 
 
 
 
$
3,235,594

Schedule of future amortization expense
Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2018 is as follows (in thousands):
2019
$
545,757

2020
$
461,267

2021
$
419,045

2022
$
403,142

2023
$
372,939

Schedule of intangible asset impairment charges including goodwill
During the three months ended March 31, 2019 and 2018, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):
 
Three Months Ended March 31,
 
2019
 
2018
Goodwill impairment charges
$
86,000

 
$
391,000

Other intangible asset impairment charges
$
78,700

 
$
54,200